Behind every successful active, there is a powerful delivery system.

Actives make sense only if they can reach their target and fully perform their intended functions. Formulas including actives therefore must be stable and properly absorbed by the skin before they release their actives.

In addition, formulas should be eudermic and not overwork the skin, keeping it in a healthy state. They should also offer a good skin feel index and appearance; therefore, the choice of excipients has a crucial role in optimizing the efficacy of actives, leading to high performance.

Among the many appropriate Vevy Europe ingredients that satisfy these requirements is?Xalifin-15?(INCI: C10-20 Acid PEG-8 Ester), the only O/W Bioemulgoid at high penetration capacity and high releasing power.?This highly safe ingredient is obtained from botanical fatty acids and polyethylene glycol, and is free from ethylene oxide and 1,4-dioxane residuals.?Enzymotoxicity tests confirm its safety: Xalifin-15 does not affect the physiological skin?biochemistry, reason why it is called Bioemulgoid.

Since 1959, Xalifin-15 has been widely used in registered dermo-pharmaceutical products and functional cosmetics.?Besides having bio-compatibility, it is highly compatible with a wide range of ingredients such as polar and non-polar lipids, silicones, acids, salts, strong electrolytes, essential oils, pharmaceutical and cosmetic actives. Indeed, this?self-emulsifying base (HLB 12) can produce stable emulsions, characterized by an excellent skin feel index and glossy appearance, ease of spreadabilty and proper absorption into skin.

Evidence through radio isotopes and fluorescein studies confirm its great penetration capacity. Other specific studies prove faster actives delivery, in comparison with common excipients.

In the light of all the above, Xalifin-15 enables the modulation of actives content, and therefore the formulation of finished products with the best performances.?All related studies are available for consultation.?

Visit?www.vevy.com?or contact?[email protected]?for further information.